Blogs, insights, guides and videos on India's unlisted market — all in one place.
<p>India’s oil scene just recorded a surprising twist — and Nayara Energy is at the centre of it.</p> <p>After months of pressure from EU sanctions, the Rosneft-backed refiner has suddenly doubled its fuel exports in November. From 75,000 barrels per day in October to <strong>150,000 barrels per day (bpd)</strong> in November — its <strong>highest level since March</strong>.</p> <p>So, what changed?</p> <h3><strong>A) How Did the Sanctions Change the Game?</strong></h3> <p>Back in July, the European Union slapped sanctions on Nayara. While the US hasn’t targeted the refiner directly, Rosneft — Nayara’s main shareholder — has been sanctioned, adding indirect pressure.</p> <p>The impact was immediate:</p> <ul data-spread="false"> <li> <p>Difficulty sourcing crude oil</p> </li> <li> <p>Disrupted export channels</p> </li> <li> <p>Shipping partners backing out to avoid regulatory trouble</p> </li> </ul> <p>But disruption also forced innovation.</p> <h3><strong>B) Russia Becomes the Lifeline</strong></h3> <p>Nayara now sources <strong>100% of its crude from Russia</strong>. In November alone, it imported <strong>408,000 bpd</strong>, the highest since May. And because Russian crude is available at a steep discount due to global sanctions, Nayara has found itself operating very close to its <strong>maximum profitable capacity</strong>.</p> <p>Cheaper crude → lower refining cost → higher margins → more exports.</p> <h3><strong>C) New Buyers, New Routes, New Strategy</strong></h3> <p>With old markets becoming harder to access, Nayara has expanded into <strong>new destinations</strong>:</p> <ul data-spread="false"> <li> <p>Bahamas</p> </li> <li> <p>Taiwan</p> </li> <li> <p>Sudan</p> </li> <li> <p>Brazil</p> </li> <li> <p>Turkey</p> </li> </ul> <p>Interestingly, almost <strong>one-third of Nayara’s exports didn’t go directly to a final customer</strong>. Instead, they traveled through <strong>ship-to-ship (STS) hubs</strong> like <strong>Fujairah (UAE)</strong> and <strong>Sohar (Oman)</strong> — both known for helping obscure the final destination of sensitive oil cargoes.</p> <p>This isn’t unheard of. <strong>Iran</strong> and <strong>Russia</strong> routinely use the same tactic to avoid sanction-linked scrutiny.</p> <h3><strong>D) Why the Sudden Export Sprint?</strong></h3> <p>A mix of factors worked in Nayara’s favour:</p> <ul data-spread="false"> <li> <p>Refining capacity back near optimal levels</p> </li> <li> <p>Discounted Russian crude supply</p> </li> <li> <p>Shrinking Russian refined exports (after Ukrainian drone attacks)</p> </li> <li> <p>New buyers willing to deal despite sanctions</p> </li> <li> <p>Flexible logistics networks using STS and transshipment hubs</p> </li> </ul> <p>In short, the company is capitalizing on a reshuffled global oil market where traditional trade lines have blurred.</p> <h3><strong>The Bigger Picture</strong></h3> <p>This export surge signals something larger:</p> <ul data-spread="false"> <li> <p>India is emerging as a key refining hub in a post-sanctions world.</p> </li> <li> <p>Refiners like Nayara benefit from buying cheap Russian crude and selling refined fuel at global prices.</p> </li> <li> <p>Countries avoiding direct purchase from Russia find Indian fuel a convenient workaround.</p> </li> </ul> <p>In other words, <strong>India is becoming the middleman in global energy rerouting.</strong></p> <h3><strong>E) So What Happens Next?</strong></h3> <p>If geopolitical conditions remain unchanged, Nayara’s model could continue thriving:</p> <ul data-spread="false"> <li> <p>High import volumes</p> </li> <li> <p>Flexible export routing</p> </li> <li> <p>Expansion into sanction-neutral markets</p> </li> </ul> <p>But the risk remains:</p> <ul data-spread="false"> <li> <p>Any future secondary sanctions</p> </li> <li> <p>Increased scrutiny of ship-to-ship transfers</p> </li> <li> <p>Volatility in Russian crude availability</p> </li> </ul> <p>For now, though, Nayara has found its rhythm — and it’s exporting at full volume.</p> <h3><strong>The Takeaway</strong></h3> <p>A few months ago, sanctions threatened to cripple Nayara Energy.</p> <p>Today, with discounted Russian supply and creative trade logistics, the company is not just surviving — it’s scaling up.</p> <p>The oil market may be global, but right now, <strong>Nayara’s playbook is hyper-local, opportunistic, and working.</strong></p>
<p>OYO is preparing for a ₹6,650 crore IPO with key moves like expanding authorised share capital and issuing bonus shares one for nineteen. This short breaks down how these steps boost liquidity, adjust ESOPs and preference share conversions, and set up OYO for its market debut. Subscribe for more quick IPO and market updates.</p>
<p>If you're an existing shareholder of <strong>Cheelizza Pizza India Limited</strong>, you’ve just been handed something interesting — a fresh rights issue served with a topping of expansion plans, discounted pricing, and a taste of opportunity.</p> <p>Let’s decode it clearly, just like a simple pizza order: no confusion, no extra fluff.</p> <h3><strong>A) What Is a Rights Issue? (Quick Refresher)</strong></h3> <p>A rights issue is when a company offers existing shareholders the chance to buy more shares at a <strong>discounted price</strong>, before offering them to outsiders.<br />It’s the company’s way of saying:</p> <blockquote> <p><em>“You believed in us early — want more shares before everyone else?”</em></p> </blockquote> <p>For Cheelizza, this route raises funds <strong>without giving up too much control</strong>, keeping ownership within the current shareholder circle.</p> <h3><strong>B) Cheelizza’s Journey So Far</strong></h3> <p>Founded in <strong>2013</strong> with a single outlet in <strong>Kandivali (Mumbai)</strong>, Cheelizza now operates <strong>16 stores</strong> across Maharashtra and Gujarat. The company has scaled from:</p> <ul data-spread="false"> <li> <p><strong>Monthly revenue:</strong> ~₹30 lakh (early days)</p> </li> <li> <p><strong>Vision:</strong> 100+ stores within two years</p> </li> <li> <p><strong>Goal:</strong> Build a <strong>global Indian vegetarian food brand</strong></p> </li> </ul> <p>With a niche position in India’s <strong>veg-only quick service restaurant (QSR) space</strong>, Cheelizza is betting on rising demand for regional tastes and vegetarian comfort food.</p> <h3><strong>C) The Rights Issue — Key Terms</strong></h3> <p><img src="https://unlistedzone.com/storage/knowledge-logo/app_image-1764655502.jpg" alt="" width="50%" /></p> <p>Shareholders can also <strong>renounce</strong> their rights — meaning they can sell their entitlement instead of subscribing.</p> <h3><strong>D) Where Will The Money Go?</strong></h3> <p>The net proceeds are earmarked for:</p> <ul data-spread="false"> <li> <p><strong>Working capital</strong></p> </li> <li> <p><strong>Setting up new outlets</strong></p> </li> <li> <p><strong>General corporate use</strong></p> </li> </ul> <p>Simply put, the capital will fund <strong>aggressive expansion</strong> — the company wants to scale fast before competitors close the gap.</p> <h3><strong>E) Financial Snapshot</strong></h3> <p>Revenue growth shows momentum, but the bottom line remains in the red — a common pattern in early-stage QSR scaling.</p> <p><img src="https://unlistedzone.com/storage/knowledge-logo/app_image-1764655557.jpg" alt="" width="50%" /></p> <p>Losses are driven by:</p> <ul data-spread="false"> <li> <p>Store expansion costs</p> </li> <li> <p>High rentals</p> </li> <li> <p>Marketing and branding</p> </li> <li> <p>Supply chain setup</p> </li> </ul> <p>In fast-scaling retail and F&B businesses, profitability generally comes after operational scale crosses a threshold — similar to brands like <strong>Wow! Momo, Biryani Blues, and Burger Singh</strong> in their early years.</p> <h3><strong>F) Should Shareholders Subscribe?</strong></h3> <p>As a shareholder, you have four options:</p> <ol start="1" data-spread="false"> <li> <p><strong>Subscribe fully</strong></p> </li> <li> <p><strong>Subscribe partially</strong></p> </li> <li> <p><strong>Renounce your rights entitlement</strong></p> </li> <li> <p><strong>Apply for additional shares (if available)</strong></p> </li> </ol> <p>A rights issue at a discount can help:</p> <ul data-spread="false"> <li> <p><strong>Average down holding cost</strong></p> </li> <li> <p><strong>Increase ownership</strong></p> </li> <li> <p>Support the brand’s <strong>growth phase</strong></p> </li> </ul> <p>However, risks remain — losses continue, and execution in the QSR sector is capital-intensive and competitive.</p> <h3><strong>G) Industry Context</strong></h3> <p>India’s QSR market is expanding rapidly, with vegetarian offerings becoming a strong differentiator. With global chains largely non-vegetarian in positioning, Cheelizza is building a <strong>veg-only niche</strong> — a potentially scalable customer segment in India and abroad.</p> <h3><strong>Bottom Line</strong></h3> <p>Cheelizza isn’t just serving pizzas — it’s trying to build a scalable, vegetarian-first QSR ecosystem. The rights issue signals <strong>confidence, growth ambitions, and shareholder-first capital raising</strong>.</p> <p>For current shareholders, this issue represents:</p> <p><strong>A chance to buy more equity at a lower price — if you believe the story is still early.</strong></p> <p>The clock is ticking — the offer closes on <strong>28 December 2025</strong>.</p> <div><hr /></div> <p><em>Disclaimer: UnlistedZone is not a SEBI-registered Research Analyst or Investment Advisor. All information provided on our platform is strictly for educational and informational purposes. We do not offer investment advice or stock recommendations. Investors are advised to conduct their own due diligence or consult a SEBI-registered advisor. Investments in unlisted and pre-IPO shares are subject to market risks including illiquidity and volatility. UnlistedZone does not assure any returns or accept liability for investment outcomes based on this report.</em></p>
<p>India’s health insurance market is booming. More people are buying medical cover, hospitals are charging more than ever, and insurers are racing to grow. Right in the middle of this rush is <strong>Care Health Insurance (formerly Religare Health Insurance)</strong> — a company backed by Religare Enterprises, Union Bank of India and Corporation Bank.</p> <p>Care sells everything from basic health plans to maternity covers, personal accident, critical illness, travel plans and corporate group policies. And in the first half of FY26, the company clearly grew. But growth alone doesn’t decide the winner in health insurance. <strong>The real test is whether an insurer can pay its claims efficiently.</strong></p> <h3>Growth Is Coming In, But Carefully</h3> <p>Between April and September 2025, Care earned <strong>₹3,377 crore in premiums</strong>, compared to <strong>₹3,137 crore</strong> in the same period last year. More people bought policies, distribution continued to work well, and demand is definitely not a problem.</p> <p>However, even while selling more, the company played safe. It passed a higher portion of risk to reinsurers — a move insurers generally take when they sense medical payouts are rising. In other words, <strong>Care grew, but didn’t want to keep all the risk on its books.</strong></p> <p>One thing clearly worked in its favour — <strong>investment income</strong>. Thanks to high interest rates, Care earned <strong>₹222 crore from interest and dividend income</strong>, up from <strong>₹161 crore</strong> last year. This investment cushion actually rescued the company from a much worse bottom-line outcome.</p> <h3>Hospitals Had Other Plans</h3> <p>Hospitals are becoming expensive faster than insurers can adjust pricing. That reality hit Care hard. Claims rose sharply to <strong>₹2,480 crore</strong>, compared to <strong>₹2,043 crore</strong> a year ago. Meanwhile, other costs didn’t help much. Commission outgo stood at <strong>₹627 crore</strong>, while fee and operating expenses were <strong>₹573 crore</strong>.</p> <p>Add all this up and you get a painful number: <strong>Care reported an operating loss of nearly ₹70 crore</strong> in the first half of FY26. Last year, it was closer to a break-even number of <strong>₹–3.58 crore</strong>. More business came in, but it got eaten up by medical bills.</p> <h3>Profit Didn’t Just Fall… It Shrunk</h3> <p><img src="https://unlistedzone.com/storage/knowledge-logo/app_image-1763639116.jpg" alt="" width="50%" /></p> <p>The real squeeze becomes clear when you look at the core insurance business. Care’s operating profit from underwriting slipped into a deeper loss of <strong>₹–70 crore</strong>, compared to a near breakeven <strong>₹–3.58 crore</strong> last year. That means the company sold more policies, but medical payouts rose so sharply that the insurance business itself turned unprofitable.</p> <p>The only reason the bottom line didn’t look worse was <strong>other income</strong>, which stood at <strong>₹88 crore</strong>, slightly higher than last year’s <strong>₹80 crore</strong>. Thanks to that cushion, Care managed to report a <strong>PAT of ₹17 crore</strong>, though that still looks tiny when compared to <strong>₹61 crore</strong> a year ago.</p> <p>In simple terms, <strong>profits didn’t decline because business was weak. They shrunk because hospitals got expensive.</strong></p> <h3>The Real Problem Isn’t Growth. It’s Inflation.</h3> <p>Care is still selling policies, premiums are rising, and investment performance is strong. But the one metric that tells the whole truth — <strong>the combined ratio</strong> — is now above 1. That means Care is <strong>paying more in claims and expenses than it earns from underwriting</strong>. The business is surviving because investments are supporting it — which won’t always remain favourable.</p> <p>So the real question isn’t:<br /><strong>“How fast can Care grow?”</strong><br />It is:<br /><strong>“How quickly can Care control its medical payouts?”</strong></p> <p>If the company tightens pricing, improves claims management and uses reinsurance more strategically, profitability can bounce back. Until then, the business will keep growing… just not profitably.<br /><br /><strong>Disclaimer:</strong></p> <p>UnlistedZone is not a SEBI-registered Research Analyst or Investment Advisor. All information provided on our platform is strictly for educational and informational purposes. We do not offer investment advice or stock recommendations. Investors are advised to conduct their own due diligence or consult a SEBI-registered advisor. Investments in unlisted and pre-IPO shares are subject to market risks including illiquidity and volatility. UnlistedZone does not assure any returns or accept liability for investment outcomes based on this report.</p>
Indicative prices, company research and your enquiries — in your pocket. Get price notes on the names you follow and reach our team from anywhere.
